Information Provided By: 
Fly News Breaks for March 4, 2019
IMGN
Mar 4, 2019 | 07:08 EDT
H.C. Wainwright analyst Debjit Chattopadhyay downgraded ImmunoGen to Neutral from Buy and lowered his price target for the shares to $3.50 from $18 following the Forward I trial failure. "Yes, there is a clear signal; unfortunately, revalidation could be three years away for an otherwise nascent pipeline," Chattopadhyay tells investors in a research note.
News For IMGN From the Last 2 Days
There are no results for your query IMGN
